Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 3.68% or 0.37 points on Tuesday and made its way into the gainers of the day. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.09 by $0.10. Finally, TheStreet raised shares of Achillion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, November 6th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a "hold" rating to a "buy" rating and set a $10.00 target price for the company in a research note on Friday, November 6th. The company earned $33.82 million during the quarter, compared to analysts' expectations of $32.62 million. The stock has a consensus rating of "Hold" and an average target price of $13.67. Achillion Pharmaceuticals, Inc.is up 58.84% in the last 3-month period. The stock was sold at an average price of $10.17, for a total value of $5,593,500.00. Following the completion of the transaction, the director now directly owns 31,431 shares of the company's stock, valued at approximately $319,653.27.
In other news, Director Nicole Vitullo sold 550,000 shares of the company's stock in a transaction dated Wednesday, November 11th. The disclosure for this sale can be found here. Analysts anticipate that Achillion Pharmaceuticals; Inc. will post ($0.12) EPS for the current fiscal year.
The stock's 50 Day Moving Average sits at 9.89, based on technical valuation. The stock's market capitalization is $1.40 billion.
A number of analysts recently commented on ACHN shares. Jefferies Group lowered their target price on shares of Achillion Pharmaceuticals from $8.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, October 15th.
Shares of Achillion Pharmaceuticals, Inc. rose by 6.22% in the last five trading days and 2.66% for the last 4 weeks. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The institutional investor purchased 14,400 shares of the biopharmaceutical company's stock, valued at approximately $100,000. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.
